Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.34208 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Clara Hwang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Henry Ford Health, Detroit, Michigan. Hauptthemen laut MEDLINE: Precision Medicine, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown.
Objective
To compare precision medicine data and outcomes between Black and White men with mCRPC. Design, Setting, and Participants This retrospective cohort study used data collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry with linked clinicogenomic data, from April 2020 to December 2021. Participants included Black and White patients with mCRPC with molecular data. Data were analyzed from December 2021 to May 2023. Exposures Database-reported race and ethnicity. Main Outcomes and Measures The primary outcome was the frequency of actionable molecular data, defined as the presence of mismatch repair deficiency (MMRD) or high microsatellite instability (MSI-H), homologous recombination repair deficiency, or tumor mutational burden of 10 mutations per megabase or greater. Secondary outcomes included the frequency of other alterations, the type and timing of genomic testing performed, and use of targeted therapy. Efficacy outcomes were prostate-specific antigen response rate, site-reported radiographic response, and overall survival.
Results
A total of 962 eligible patients with mCRPC were identified, including 204 Black patients (21.2%; median [IQR] age at diagnosis, 61 [55-67] years; 131 patients [64.2%] with Gleason scores 8-10; 92 patients [45.1%] with de novo metastatic disease) and 758 White patients (78.8%; median [IQR] age, 63 [57-69] years; 445 patients [58.7%] with Gleason scores 8-10; 310 patients [40.9%] with de novo metastatic disease). Median (IQR) follow-up from mCRPC was 26.6 (14.2-44.7) months. Blood-based molecular testing was more common in Black men (111 men [48.7%]) than White men (317 men [36.4%]; P < .001). Rates of actionable alterations were similar between groups (65 Black men [32.8%]; 215 White men [29.1%]; P = .35), but MMRD or MSI-H was more common in Black men (18 men [9.1]) than White men (36 men [4.9%]; P = .04). PTEN alterations were less frequent in Black men than White men (31 men [15.7%] vs 194 men [26.3%]; P = .003), as were TMPRSS alterations (14 men [7.1%] vs 155 men [21.0%]; P < .001). No other differences were seen in the 15 most frequently altered genes, including TP53 , AR , CDK12 , RB1 , and PIK3CA . Matched targeted therapy was given less frequently in Black men than White men (22 men [33.5%] vs 115 men [53.5%]; P = .008). There were no differences in response to targeted therapy or survival between the two cohorts. Conclusions and Relevance This cohort study of men with mCRPC found higher frequency of MMRD or MSI-H and lower frequency of PTEN and TMPRSS alterations in Black men compared with White men. Although Black men received targeted therapy less frequently than White men, no differences were observed in clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Henry Ford Health, Detroit, Michigan.
- University of Michigan, Ann Arbor, Michigan.
- Wayne State University School of Medicine, Detroit, Michigan.
- Karmanos Cancer Institute, Detroit, Michigan.
- Tulane University, New Orleans, Louisiana.
- Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, North Carolina.
Zitieren
APA
Hwang, C., Henderson, N. C., Chu, S. C., Holland, B., Cackowski, F. C., Pilling, A., Jang, A., Rothstein, S., Labriola, M., Park, J. J., Ghose, A., Bilen, M. A., Mustafa, S., Kilari, D., Pierro, M. J., Thapa, B., Tripathi, A., Garje, R., Ravindra, A., …, & Barata, P. C. (2023). Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.34208
Vancouver
Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, et al. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.34208
BibTeX
@article{Hwang2023,
author = {Hwang, Clara and Henderson, Nicholas C and Chu, Shih-Chun and Holland, Brandon and Cackowski, Frank C and Pilling, Amanda and Jang, Albert and Rothstein, Shoshana and Labriola, Matthew and Park, Joseph J and Ghose, Alyssa and Bilen, Mehmet A and Mustafa, Seema and Kilari, Deepak and Pierro, Michael J and Thapa, Bicky and Tripathi, Abhishek and Garje, Rohan and Ravindra, Aditya and Koshkin, Vadim S and Hernandez, Erik and Schweizer, Michael T and Armstrong, Andrew J and McKay, Rana R and Dorff, Tanya B and Alva, Ajjai S and Barata, Pedro C},
title = {Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.34208}
}
EUVIMED